Publications
Detailed Information
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyo-Pyo | - |
dc.contributor.author | Seo, Sang-Soo | - |
dc.contributor.author | Ryu, Sang-Young | - |
dc.contributor.author | Kim, Jong-Hyeok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Park, Sang-Yoon | - |
dc.contributor.author | Nam, Joo-Hyun | - |
dc.contributor.author | Kang, Soon-Beorn | - |
dc.contributor.author | Lee, Kyung-Hee | - |
dc.contributor.author | Song, Yong Sang | - |
dc.date.accessioned | 2010-01-29 | - |
dc.date.available | 2010-01-29 | - |
dc.date.created | 2018-03-08 | - |
dc.date.issued | 2008-06 | - |
dc.identifier.citation | Gynecologic Oncology, Vol.109 No.3, pp.359-363 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.other | 28789 | - |
dc.identifier.uri | https://hdl.handle.net/10371/46577 | - |
dc.description.abstract | Background. To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. Methods. We enrolled 24 patients with recurrent ovarian cancer, of median age 54 years (range, 39-64). Eleven patients had measurable lesions on CT scan, and the other 13 had increased serum CA-125 levels. Eighteen patients had platinum-sensitive disease (minimum treatment free interval >= 6 months) and 6 had platinum-resistant disease (minimum treatment free interval < 6 months). CKD-602 (0.5 mg/m(2)/day) was administered intravenously for 5 days every 3 weeks. The median number of courses per patient was 6 (range, I to 12). Response was evaluated by the evaluation of the size of the mass by CT scan and CA-125 response. Results. The overall response rate was 45.0% (9/20), with 4 patients exhibiting partial responses and 5 patients exhibiting 75% CA-125 responses in 20 evaluable patients. Of the 9 responsive patients, 8 were platinum-sensitive (8/15, 53.3%) and I was platinum-resistant (115, 20.0%). An additional 5 patients showed stable disease, whereas 6 patients exhibited progressive lesions. Of 24 patients, the most common toxicity was hematological, with grades 3 or 4 neutropenia developing in all 24 patients (100%) and in 94 cycles (71.7%). Grade 3 thrombocytopenia developed in 4 patients (16.7%) and 6 cycles (4.6%). None of the patients experienced grades 3 and 4 gastrointestinal toxicities, including nausea, vomiting, and anorexia. Conclusions. The newly developed topoisomerase I inhibitor, CKD-602, showed activity against both platinum-sensitive and -resistant ovarian cancer, with acceptable toxicity. (c) 2007 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | Academic Press | - |
dc.title | Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1016/j.ygyno.2007.11.023 | - |
dc.citation.journaltitle | Gynecologic Oncology | - |
dc.identifier.wosid | 000256892900009 | - |
dc.identifier.scopusid | 2-s2.0-44449179985 | - |
dc.citation.endpage | 363 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 359 | - |
dc.citation.volume | 109 | - |
dc.identifier.sci | 000256892900009 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Hyo-Pyo | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kang, Soon-Beorn | - |
dc.contributor.affiliatedAuthor | Song, Yong Sang | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GYNECOLOGIC-ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | SALVAGE THERAPY | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | TOPOTECAN | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | CA-125 | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordAuthor | ovarian cancer | - |
dc.subject.keywordAuthor | recurrent | - |
dc.subject.keywordAuthor | CKD-602 | - |
dc.subject.keywordAuthor | topoisomerase I | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.